Scripps calls off controversial merger talks with USC; Rottapharm calls off IPO; Sandoz to move U.S. HQ;

@FierceBiotech: Wall Street wonders what Shire is worth. Report | Follow @FierceBiotech

@JohnCFierce: Merck vet steps in to lead Third Rock's immuno-oncology upstart. Item | Follow @JohnCFierce

@DamianFierce: and DMD docs are upbeat on 144-week eteplirsen data, but shares are down about 10%. Article | Follow @DamianFierce

@EmilyMFierce: Faculty calls for removal of Scripps' leader amid USC merger talks. FierceBiotech Research story | Follow @EmilyMFierce

> Facing some stiff opposition from staff scientists, Scripps Research Institute has called off talks with USC about a possible merger. The talks were triggered by a large operating deficit and declining NIH grants, a trend that has rattled a number of top research centers. But Scripps faculty responded to the prospect of a merger by calling for the ouster of President Michael Marletta, saying that they've lost confidence in his leadership abilities. Release

> Italy's Rottapharm Madaus has scrapped plans for an IPO, responding to a dwindling appetite for new offerings and a full banquet to choose from. Story

> Sandoz is moving to a new U.S. base in New Jersey, taking over a building vacated by Novo Nordisk ($NVO) a year ago. Story

Medical Device News

@FierceMedDev: We're looking for the fiercest companies in med tech for our 2014 Fierce 15 awards. More details here | Follow @FierceMedDev

@StacyALawrence: Zimmer, Biomet hit regulatory speedbump in pending merger. Story | Follow @StacyALawrence

@VarunSaxena2: JAMA study adds to robotic surgery safety concerns. Article | Follow @VarunSaxena2

@MichaelGFierce: MIT, MicroCHIPS develop remote-controlled contraceptive with on-off delivery. FierceDrugDelivery story | Follow @MichaelGFierce

@EmilyWFierce: laid out its new strategic plan for developing therapies for rare childhood diseases. PMLiVE article | Follow @EmilyWFierce

> USGI Medical fills enrollment for pivotal U.S. study of its incisionless, endoscopic weight loss procedure. Story

> FDA clears oral sleep apnea device as search for alternatives to CPAP therapy continues. Report

> Gynesonics aims for $35M for minimally invasive uterine fibroid device. Article

Pharma News

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Report | Follow @FiercePharma

@EricPFierce: Health Canada tells GSK to get its vaccine house in order as flu season approaches. More | Follow @EricPFierce

@CarlyHFierce: M&A spotlight: Allergan plots cost cuts to ward off Valeant, AbbVie may have to raise Shire bid--again. Story | Follow @CarlyHFierce

> NICE likes Lundbeck's alcohol-addiction drug Selincro. Article

> Insurers balk at pricey generic version of ancient GSK heart drug. Story

Vaccines News

> U.S. bioterror readiness highlighted after NIH smallpox discovery. Article

> Could soaring vaccine prices spark Sovaldi-style payer pushback? Story

> No link between Merck's Gardasil and blood clots, study says. Item

> Report: Manufacturing, logistical challenges to weigh down cancer vaccine market through 2022. More

> Canada gives GSK 30-day deadline for turnaround plans at FluLaval plant. Article

Pharma Manufacturing News

> Report: Dendreon's costly manufacturing casts doubt on cancer vax viability. Article

> Portfolio trimming by generic manufacturers linked to soaring drug costs. Item

> Global CMOs tipped to enter Russia as local drug production deadline nears. Story

> Serum Institute allies with biotech in bid to cut cost of biosimilar production. More

> India faces higher QC costs as Shasun shows value of compliance. Article

> U.K. commits cash to $24.7M industry-focused formulation center. Story

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.